This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both of these medicines can affect your kidneys.
What might happen:
Using these medicines together may increase your risk of kidney damage.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may instruct you to drink extra water before and after your zoledronic acid therapy. Your doctor may want to perform blood tests to check your kidney function before and after your zoledronic acid therapy.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Aclasta (zoledronic acid) Canadian prescribing information. Novartis Pharmaceuticals Canada Inc. September 11, 2014.
2.Reclast (zoledronic acid) US prescribing information. Novartis April, 2015.
3.USFood and Drug Administration. FDA Drug Safety Communication: New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). available at: http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm September 1, 2011.